Post by FDA

The adequacy of the nation’s blood supply depends not only on volunteer blood donations, but also on a resilient and secure supply chain of equipment, collection systems, solutions, and devices used to collect, manufacture, and transfuse blood and blood components.   FDA’s Center for Biologics Evaluation and Research (CBER) is responsible for regulation of the nation’s blood supply. Learn how CBER evaluates Blood License Applications in its effort to maintain the U.S blood supply: https://lnkd.in/gt66SN8r CBER teams are continually addressing supply chain issues that could affect the availability of critical blood collection and transfusion products. These efforts underscore the importance of strengthening what remains a critical supply chain. To advance this work, FDA will convene a roundtable this fall focused on identifying supply chain gaps, discussing risks, and exploring practical mitigation strategies to enhance resilience across the blood supply ecosystem. The workshop date and preliminary agenda will be announced soon.